Form 4: Halozyme Therapeutics CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Halozyme Therapeutics' CEO, Helen Torley, executed stock options and sold shares between September 24 and September 26, 2024, under a pre-arranged trading plan.

Summary

• Helen Torley, the President and CEO of Halozyme Therapeutics, exercised options to purchase common stock at a price of $13.87 per share on September 24, 25 and 26, 2024.
• Concurrently, she sold 10,000 shares of common stock on each of those days.
• The sales on September 24 occurred at a weighted average price of $58.21, with prices ranging from $57.77 to $58.525.
• The sales on September 25 occurred at a weighted average price of $56.337, with prices ranging from $56.10 to $56.58.
• The sales on September 26 occurred at a weighted average price of $56.097, with prices ranging from $55.84 to $56.47.
• These transactions were executed under a pre-arranged trading plan adopted on March 22, 2024, in accordance with Rule 10b5-1.
• Following these transactions, Torley directly owns 676,744 shares of Halozyme Therapeutics common stock.
• She also holds options to purchase 20,000 shares of common stock at $13.87.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. However, any insider selling can create some uncertainty.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales were not based on insider information.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although the pre-arranged trading plan mitigates this concern.

Risks

• While the 10b5-1 plan mitigates concerns, significant sales by a key executive could still create short-term market uncertainty.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The exercise of options and subsequent sale of shares is a typical part of executive compensation and wealth management.
• The use of a 10b5-1 trading plan is a common practice among executives to ensure compliance with insider trading regulations, similar to practices seen at companies like Amgen and Regeneron.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The pre-arranged nature of the transactions should minimize any significant impact.

Key Dates